A patient with blink-triggered visual tilt shows a cortical lesion that initially mimicked a peripheral vestibular disorder.

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Debio 4126 is intended for intramuscular injection every three months.

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. If consummated, the deal would bring ...

The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million. Ipsen is ...

The treatment of choice for Cushing's syndrome remains surgical. The role for medical therapy is twofold. Firstly it is used to control hypercortisolaemia prior to surgery to optimize patient's ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow's standards of care in oncology and rare diseases, today announced that the first patient has ...